Advanced Nanotechnology-Based Strategies for the Targeted and Enhanced Delivery of Phytopharmaceuticals: Mechanistic Insights, Formulation Techniques, and Translational Applications

Hiroshi Takumi Sato [1*], Keiko Naomi Yamamoto [2], Tatsuya Kenji Fujimura [3], Ayaka Midori Nakamura [4]
[1] PhD, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan
[2] PhD, Center for Nanobiomedical Innovation, Osaka University, Japan
[3] PhD, Department of Drug Delivery Research, Kyoto University, Japan

* Corresponding Author: **Hiroshi Takumi Sato**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 02
March – April 2024
Received: 17-01-2024
Accepted: 18-02-2024
Published: 21-03-2024
Page No: 112-127

Abstract
Phytopharmaceuticals, derived from medicinal plants, have demonstrated significant therapeutic potential across numerous disease states; however, their clinical utility is often compromised by poor aqueous solubility, limited membrane permeability, rapid hepatic metabolism, and low systemic bioavailability. Conventional delivery approaches fail to address these pharmacokinetic limitations, resulting in suboptimal therapeutic outcomes and necessitating higher doses that may increase toxicity risks. Nanotechnology-based delivery systems have emerged as transformative platforms to overcome these challenges by encapsulating bioactive phytochemicals within nanocarriers such as nanoparticles, liposomes, nanoemulsions, polymeric carriers, and dendrimers. This review comprehensively examines the mechanistic basis by which these nanosystems enhance solubility, protect labile compounds from degradation, facilitate cellular uptake, enable controlled release kinetics, and achieve targeted delivery to specific tissues and cellular compartments. Preclinical studies across various animal models have consistently demonstrated superior pharmacokinetic profiles, enhanced bioavailability, prolonged circulation times, and improved therapeutic efficacy compared to free phytochemicals. Emerging clinical evidence further supports the translational potential of these nanoformulations in human populations. Critical considerations regarding biocompatibility, toxicity profiles, scalability of manufacturing processes, and regulatory frameworks are discussed in detail. Finally, future perspectives on personalized phytopharmaceutical nanotherapy, integration with precision medicine paradigms, and innovative formulation strategies are presented, highlighting the promise of nanotechnology to revolutionize the delivery and clinical application of plant-derived therapeutics in modern healthcare systems.

DOI:

Keywords: Nanotechnology, Phytopharmaceuticals, Targeted delivery, Nanocarriers, Bioavailability, Pharmacokinetics, Controlled release, Translational medicine

Introduction

Phytopharmaceuticals represent a diverse class of bioactive compounds isolated from medicinal plants that have been utilized for centuries in traditional medicine systems worldwide [1]. These natural products encompass alkaloids, flavonoids, terpenoids, polyphenols, glycosides, and numerous other chemical entities that exhibit pharmacological activities including antioxidant, anti-inflammatory, anticancer, antimicrobial, cardioprotective, and neuroprotective effects [2]. Despite their therapeutic promise, the translation of phytopharmaceuticals into clinically effective medicines has been substantially hindered by inherent physicochemical and biopharmaceutical limitations [3]. Many phytochemicals exhibit extremely poor aqueous solubility, belonging to Biopharmaceutics Classification System Class II or IV compounds, which fundamentally restricts their dissolution in gastrointestinal fluids and subsequent absorption across biological membranes [4]. Additionally, these compounds frequently

demonstrate low lipophilicity and inadequate membrane permeability, further diminishing their ability to traverse cellular barriers [5].

The oral bioavailability of most phytopharmaceuticals remains disappointingly low, often less than five percent, due to extensive first-pass hepatic metabolism, efflux transporter activity, chemical instability in physiological environments, and rapid systemic clearance [6]. Curcumin, resveratrol, quercetin, and catechins exemplify phytochemicals with exceptional *in vitro* biological activities but severely limited *in vivo* efficacy attributable to these pharmacokinetic deficiencies [7]. Conventional formulation strategies, including simple encapsulation, complexation with cyclodextrins, or preparation of solid dispersions, have achieved only modest improvements in bioavailability and fail to address the multifaceted challenges comprehensively [8]. Furthermore, the lack of tissue-specific targeting with conventional delivery results in off-target distribution, necessitating administration of substantially higher doses to achieve therapeutic concentrations at disease sites, thereby increasing the risk of systemic toxicity and adverse effects [9].

Nanotechnology has emerged as a revolutionary approach to pharmaceutical sciences, offering unprecedented opportunities to engineer delivery systems at the molecular and supramolecular scale [10]. Nanocarrier-based delivery platforms, typically ranging from 10 to 1000 nanometers in size, possess unique physicochemical properties that enable them to circumvent biological barriers, enhance drug solubility, protect encapsulated compounds from enzymatic degradation, modulate release kinetics, and achieve targeted accumulation in specific tissues through passive or active targeting mechanisms [11]. The application of nanotechnology to phytopharmaceutical delivery represents a paradigm shift that addresses fundamental limitations while preserving and potentially enhancing the inherent biological activities of plant-derived compounds [12]. This convergence of traditional phytotherapy with cutting-edge nanomedicine has generated considerable scientific interest and spawned extensive research efforts aimed at developing clinically viable nanoformulations of therapeutically relevant phytochemicals [13].

The primary objective of this comprehensive review is to critically examine the current state of knowledge regarding nanotechnology-based strategies for enhanced delivery of phytopharmaceuticals. We systematically evaluate various nanocarrier platforms including nanoparticles, liposomes, nanoemulsions, polymeric carriers, and dendrimers, analyzing their design principles, fabrication methodologies, and comparative advantages. Mechanistic insights into how these nanosystems overcome conventional delivery limitations are discussed in detail, with particular emphasis on improvements in bioavailability, pharmacokinetic profiles, cellular uptake mechanisms, and targeted delivery capabilities. Preclinical evidence from *in vitro* and *in vivo* studies is synthesized to illustrate the therapeutic benefits of nanoformulated phytopharmaceuticals across diverse disease models. Emerging clinical data demonstrating translational potential in human subjects are critically reviewed. Finally, safety considerations, regulatory challenges, and future perspectives on personalized nanophytotherapy are examined to provide a comprehensive understanding of this rapidly evolving interdisciplinary field.

Table 1: Selected phytopharmaceuticals and their conventional limitations in absorption and bioavailability

Phytopharmaceutical	Chemical Class	Primary Source	Conventional Bioavailability	Major Limiting Factors	Therapeutic Applications
Curcumin	Polyphenol	Curcuma longa	Less than 1%	Poor aqueous solubility, rapid metabolism, extensive glucuronidation	Anti-inflammatory, anticancer, neuroprotective
Resveratrol	Stilbenoid	Vitis vinifera	Approximately 0.5%	Rapid sulfation and glucuronidation, low stability	Cardioprotective, antioxidant, anti-aging
Quercetin	Flavonoid	Various plants	2-17%	Poor solubility, extensive first-pass metabolism, efflux pumps	Antioxidant, anti-inflammatory, antiviral
Epigallocatechin gallate	Catechin	Camellia sinensis	5-10%	Chemical instability, rapid degradation, poor permeability	Anticancer, metabolic regulation, neuroprotective
Silymarin	Flavonolignan	Silybum marianum	23-47%	Poor water solubility, P-glycoprotein efflux	Hepatoprotective, antioxidant, anticancer
Berberine	Alkaloid	Berberis species	Less than 5%	P-glycoprotein efflux, extensive metabolism	Antimicrobial, antidiabetic, cardiovascular
Paclitaxel	Diterpene	Taxus brevifolia	Variable	Poor solubility, P-glycoprotein substrate	Anticancer, antimitotic
Artemisinin	Sesquiterpene lactone	Artemisia annua	32%	Poor solubility, chemical instability	Antimalarial, anticancer

Challenges in Conventional Delivery of Phytopharmaceuticals

The delivery of phytopharmaceuticals through conventional routes faces multifaceted challenges that collectively compromise their therapeutic potential and clinical applicability [14]. Foremost among these challenges is the issue of aqueous solubility, as the majority of therapeutically relevant phytochemicals are highly lipophilic compounds with solubility values often below one microgram per milliliter in aqueous media [15]. This fundamental limitation directly impacts dissolution rates in gastrointestinal fluids following oral administration, creating a bottleneck in the absorption process that cannot be overcome by simply increasing the administered dose [16]. The poor solubility profile also presents formulation challenges, restricting the ability to develop stable liquid dosage forms and limiting options for parenteral administration routes [17].

Membrane permeability represents another critical barrier to effective phytopharmaceutical delivery, as many plant-derived compounds lack the optimal balance of lipophilicity and hydrophilicity required for passive diffusion across intestinal epithelial cells [18]. The structural complexity and high molecular weight of certain phytochemicals, particularly glycosides and tannins, further impede their

ability to traverse lipid bilayers efficiently [19]. Even when absorption does occur, active efflux transporters, particularly P-glycoprotein and other ATP-binding cassette transporters expressed at high levels in intestinal enterocytes, actively pump absorbed phytochemicals back into the intestinal lumen, substantially reducing net absorption and bioavailability [20]. This efflux mechanism represents an evolutionarily conserved defense system that treats many phytochemicals as xenobiotics, preventing their systemic accumulation [21].

Chemical and metabolic stability constitutes a third major challenge confronting phytopharmaceutical delivery systems [22]. Many bioactive plant compounds are inherently unstable under physiological conditions, undergoing rapid degradation in the acidic environment of the stomach, or through oxidation, hydrolysis, or isomerization reactions in intestinal fluids [23]. Curcumin exemplifies this instability, degrading within minutes at physiological pH to form ferulic acid, feruloylmethane, and vanillin derivatives that lack the parent compound's biological activity [24]. Resveratrol similarly undergoes rapid degradation and isomerization from trans to cis configuration, significantly diminishing its antioxidant and cardioprotective properties [25]. Following absorption, phytochemicals encounter extensive phase I and phase II metabolism in enterocytes and hepatocytes, where cytochrome P450 enzymes catalyze oxidative transformations while UDP-glucuronosyltransferases and sulfotransferases generate conjugated metabolites that are rapidly excreted [26].

The absence of tissue-specific targeting mechanisms in conventional formulations results in non-selective biodistribution following systemic absorption, with phytochemicals distributing broadly across multiple organ systems rather than accumulating preferentially at intended therapeutic sites [27]. This non-targeted distribution pattern necessitates administration of substantially elevated doses to achieve adequate concentrations at disease locations, inevitably increasing the likelihood of off-target effects and potential toxicity in healthy tissues [28]. Furthermore, many phytopharmaceuticals exhibit rapid systemic clearance with elimination half-lives measured in minutes to hours, requiring frequent dosing regimens that compromise patient compliance and result in significant fluctuations in plasma concentrations between peak and trough levels [29]. These pharmacokinetic limitations are particularly problematic for chronic disease management where sustained therapeutic concentrations are essential for optimal efficacy [30].

Manufacturing and formulation challenges also impede the development of conventional phytopharmaceutical products [31]. The complex mixture of compounds present in plant extracts, batch-to-batch variability in phytochemical composition, presence of interfering substances, and difficulties in achieving pharmaceutical-grade purification all contribute to inconsistencies in product quality and therapeutic outcomes [32]. Standardization of phytopharmaceutical preparations remains challenging, and the lack of robust analytical methods for quality control further complicates regulatory approval processes [33]. Additionally, many phytochemicals exhibit dose-dependent biphasic effects or hormetic responses where low and high doses produce opposite biological outcomes, making dose optimization particularly complex in the absence of predictable pharmacokinetic behavior [34].

Nanotechnology Platforms for Enhanced Delivery: Nanoparticles, Liposomes, and Nanoemulsions

Nanoparticle-based delivery systems represent one of the most extensively investigated nanotechnology platforms for phytopharmaceutical delivery, encompassing a diverse array of particle types fabricated from both organic and inorganic materials [35]. Lipid nanoparticles, including solid lipid nanoparticles and nanostructured lipid carriers, consist of biocompatible physiological lipids that remain solid at body temperature, providing a stable matrix for encapsulating lipophilic phytochemicals while protecting them from chemical and enzymatic degradation [36]. These systems are typically prepared through high-pressure homogenization, microemulsion techniques, or solvent emulsification-evaporation methods, yielding particles ranging from 50 to 500 nanometers with narrow size distributions [37]. The solid lipid core provides excellent stability during storage and prevents premature drug leakage, while surface modification with polyethylene glycol or other hydrophilic polymers can extend circulation time by reducing opsonization and reticuloendothelial system uptake [38].



Fig 1: Schematic representation of different nanocarrier systems for phytopharmaceutical delivery, including nanoparticles, liposomes, and polymeric carriers

Metallic and metal oxide nanoparticles, particularly gold, silver, and iron oxide nanoparticles, have emerged as versatile carriers for phytopharmaceutical delivery with unique physicochemical properties [39]. Gold nanoparticles can be synthesized through green chemistry approaches using plant extracts themselves as reducing and stabilizing agents, creating biocompatible particles with phytochemicals adsorbed or conjugated to the nanoparticle surface [40]. These systems exhibit excellent biocompatibility, tunable surface chemistry for ligand conjugation, and unique optical properties that enable tracking and imaging applications [41]. Iron oxide nanoparticles offer superparamagnetic properties that facilitate magnetic targeting and magnetic resonance imaging contrast enhancement, allowing simultaneous therapeutic and diagnostic applications in theranostic platforms [42]. Surface functionalization of metallic nanoparticles with targeting ligands, antibodies, or aptamers enables active targeting to specific cell types or disease sites, substantially improving the therapeutic index of delivered phytochemicals [43].

Liposomes represent another cornerstone technology in nanopharmaceutical delivery, consisting of self-assembled phospholipid bilayer vesicles that can encapsulate both hydrophilic compounds in the aqueous core and lipophilic molecules within the lipid membrane [44]. This amphipathic structure makes liposomes particularly versatile for phytopharmaceutical delivery, accommodating compounds across a broad spectrum of polarities and enabling co-delivery of multiple phytochemicals with synergistic activities [45]. Conventional liposomes are prepared through thin-film hydration, reverse-phase evaporation, or ethanol injection methods, producing unilamellar or multilamellar vesicles ranging from 50 nanometers to several micrometers [46]. The phospholipid composition can be tailored to modulate membrane fluidity, stability, and fusion characteristics, with saturated phospholipids producing more rigid membranes and unsaturated lipids yielding more fluid structures.

Stealth liposomes, modified through surface decoration with polyethylene glycol polymers, exhibit dramatically prolonged circulation times by evading recognition and clearance by the mononuclear phagocyte system. The flexible hydrophilic polyethylene glycol chains create a steric barrier that inhibits protein adsorption and complement activation, reducing opsonization and subsequent hepatic uptake. These long-circulating liposomes demonstrate enhanced accumulation in tumors and inflamed tissues through the enhanced permeability and retention effect, a passive targeting mechanism that exploits the abnormal vasculature and impaired lymphatic drainage characteristic of these pathological sites. Active targeting can be further achieved through conjugation of targeting moieties such as folate, transferrin, antibodies, or peptides to the distal end of polyethylene glycol chains, promoting receptor-mediated endocytosis in target cells overexpressing specific surface markers.

Table 2: Nanocarrier types, composition, and loading efficiency for key phytochemicals

Nanocarrier Type	Primary Components	Typical Size Range	Phytochemical Example	Loading Efficiency	Encapsulation Method	Key Advantages
Solid lipid nanoparticles	Glyceryl behenate, stearic acid, surfactants	50-500 nm	Curcumin	85-95%	Hot homogenization	High stability, controlled release
Nanostructured lipid carriers	Mixed lipids, liquid lipids, surfactants	100-400 nm	Resveratrol	80-92%	High-pressure homogenization	Enhanced loading capacity
Liposomes	Phosphatidylcholine, cholesterol	50-500 nm	Quercetin	70-85%	Thin-film hydration	Biocompatible, dual loading
PEGylated liposomes	Phospholipids, DSPE-PEG	80-200 nm	Epigallocatechin gallate	75-88%	Reverse-phase evaporation	Prolonged circulation
Polymeric nanoparticles	PLGA, PLA	100-300 nm	Silymarin	82-94%	Nanoprecipitation	Tunable degradation
Chitosan nanoparticles	Chitosan, tripolyphosphate	100-500 nm	Berberine	78-90%	Ionic gelation	Mucoadhesive, cationic
Nanoemulsions	Oil phase, surfactant, co-surfactant	20-200 nm	Paclitaxel	88-96%	High-energy emulsification	Excellent solubilization
Gold nanoparticles	Gold salts, plant extract reducing agents	10-100 nm	Multiple polyphenols	65-80%	Green synthesis	Theranostic potential

Nanoemulsions represent kinetically stable dispersions of oil and water stabilized by surfactant and co-surfactant molecules at the interface, producing droplet sizes typically below 200 nanometers. Unlike conventional emulsions that are thermodynamically unstable and prone to coalescence and creaming, nanoemulsions exhibit exceptional stability due to their small droplet size and the resulting high energy barrier against gravitational separation and aggregation. The nanoscale dimensions also confer optical transparency or translucency, making nanoemulsions aesthetically appealing for oral and topical formulations. Preparation methods include high-energy approaches such as high-pressure homogenization, ultrasonication, or microfluidization, as well as low-energy methods exploiting phase transitions or spontaneous emulsification phenomena.

Nanoemulsions provide an excellent solubilization environment for highly lipophilic phytochemicals, dramatically increasing their apparent aqueous solubility and dissolution rates. The oil phase can be selected from pharmaceutical-grade oils including medium-chain triglycerides, long-chain triglycerides, or essential oils that may themselves possess therapeutic activities, creating synergistic delivery systems. Surfactant selection is critical for nanoemulsion stability and biological performance, with food-grade surfactants such as polysorbates, lecithin, or Cremophor being preferred for oral delivery applications due to their established safety profiles. The large interfacial area of nanoemulsions facilitates rapid drug release and absorption, while incorporation of mucoadhesive polymers can prolong residence time at absorption sites. Self-

nanoemulsifying drug delivery systems represent a particularly elegant approach where the formulation exists as a stable preconcentrate that spontaneously forms nanoemulsions upon dilution with aqueous media in the gastrointestinal tract, combining stability advantages of solid dosage forms with the bioavailability enhancement of nanoemulsions.

Polymeric Carriers and Dendrimer-Based Systems

Polymeric nanoparticles have emerged as highly versatile and customizable platforms for phytopharmaceutical delivery, offering precise control over particle size, surface properties, drug loading, and release kinetics through selection of polymer composition and fabrication parameters. Biodegradable synthetic polymers, particularly poly lactic-co-glycolic acid and polylactic acid, represent the most extensively investigated materials for polymeric nanoparticle fabrication due to their excellent biocompatibility, predictable degradation kinetics, and regulatory approval status for parenteral administration. These polyesters undergo hydrolytic degradation in physiological environments to form lactic acid and glycolic acid monomers that enter normal metabolic pathways, eliminating concerns about long-term accumulation of non-degradable materials. The degradation rate can be systematically modulated by adjusting the lactide to glycolide ratio, molecular weight, and degree of crystallinity, enabling design of delivery systems with release durations ranging from days to months. Fabrication of polymeric nanoparticles typically employs nanoprecipitation, emulsion-solvent evaporation, or salting-out techniques, each offering distinct advantages in terms of process simplicity, scalability, and suitability for different drug properties. Nanoprecipitation involves dissolving polymer and phytochemical in a water-miscible organic solvent followed by rapid addition to an aqueous phase, causing instantaneous precipitation of polymer and drug into nanoparticles stabilized by surfactants or stabilizers. This technique is particularly suitable for small-scale laboratory preparation and produces particles with narrow size distributions, though encapsulation efficiency depends critically on drug-polymer compatibility and process parameters. Emulsion-solvent evaporation methods begin with formation of an oil-in-water emulsion containing dissolved polymer and drug in the organic phase, followed by solvent removal through evaporation or extraction, leading to nanoparticle hardening. This approach generally yields higher encapsulation efficiencies for lipophilic drugs but requires more intensive processing and careful control of emulsification conditions.

Natural polymers including chitosan, alginate, gelatin, and albumin offer advantages of inherent biocompatibility, biodegradability, and presence of functional groups amenable to chemical modification. Chitosan, a cationic polysaccharide derived from chitin, has attracted particular interest due to its mucoadhesive properties that promote prolonged residence time at mucosal surfaces, its ability to transiently open tight junctions between epithelial cells thereby enhancing paracellular transport, and its antimicrobial and wound-healing activities that complement therapeutic effects of loaded phytochemicals. Chitosan nanoparticles are typically prepared through ionic gelation with anionic crosslinkers such as tripolyphosphate, forming spontaneously assembled particles under mild aqueous conditions suitable for encapsulating sensitive phytochemicals without exposure to organic solvents or harsh processing conditions. Surface charge density and particle stability can be modulated by varying chitosan molecular weight, degree of deacetylation, and crosslinking density. Albumin nanoparticles leverage the natural transport functions of this abundant plasma protein, which possesses numerous ligand binding sites and undergoes receptor-mediated transcytosis across endothelial barriers. The commercially successful albumin-bound paclitaxel formulation demonstrates the clinical viability of this approach, utilizing the albumin receptor gp60 and caveolin-mediated transport to enhance tumor delivery of paclitaxel. Similar strategies have been applied to other phytochemicals including curcumin and quercetin, with albumin nanoparticles providing improved stability, extended circulation time, and enhanced tumor accumulation compared to free drugs. Preparation methods include desolvation, emulsification, or nab technology, with the latter involving high-pressure homogenization of drug and albumin under controlled conditions to produce particles approximately 130 nanometers in diameter.

Dendrimers represent a unique class of synthetic macromolecular carriers characterized by highly branched, three-dimensional architectures with well-defined molecular weights and numerous surface functional groups. Unlike conventional polymers that exhibit polydisperse molecular weight distributions, dendrimers are synthesized through iterative reaction sequences that build successive generations of branching around a central core, producing monodisperse macromolecules with precisely controlled structure. The most extensively studied dendrimer families include polyamidoamine dendrimers, poly propylene imine dendrimers, and polyester dendrimers, each offering distinct chemical properties and biological behaviors. Dendrimers can carry drug molecules through encapsulation within internal cavities, complexation with surface groups, or covalent conjugation to peripheral functional groups, with loading capacity increasing geometrically with each successive generation

The multivalent surface of dendrimers provides exceptional opportunities for simultaneous conjugation of drugs, targeting ligands, imaging agents, and solubilizing groups, enabling creation of multifunctional therapeutic platforms. Surface modification with polyethylene glycol or other hydrophilic polymers reduces the cytotoxicity associated with cationic dendrimer surfaces while enhancing aqueous solubility and circulation time. Targeted delivery can be achieved through conjugation of specific ligands such as folic acid for cancer cells overexpressing folate receptors, or peptides recognizing integrins upregulated in tumor vasculature. Dendrimer-based delivery systems have demonstrated remarkable success in improving the aqueous solubility and bioavailability of poorly soluble phytochemicals including curcumin, paclitaxel, and camptothecin derivatives, with solubility enhancements of up to several thousand-fold reported for some systems.



Fig 2: Mechanisms by which nanotechnology enhances bioavailability, stability, and targeted delivery of phytochemicals

Cyclodextrin-based nanocarriers represent another important category of polymeric delivery systems that exploit the unique molecular recognition properties of these cyclic oligosaccharides. Cyclodextrins possess a hydrophobic cavity that can accommodate lipophilic guest molecules through non-covalent inclusion complexation, while their hydrophilic exterior promotes aqueous solubility of the resulting complexes. Chemically modified cyclodextrins including hydroxypropyl, methyl, and sulfobutylether derivatives exhibit enhanced solubilizing capacity and reduced toxicity compared to parent compounds. Polymerization or crosslinking of cyclodextrin units creates nanosponges or nanogels with multiple cavities and enhanced loading capacity. These systems have shown particular promise for delivering flavonoids and other polyphenolic phytochemicals, with several cyclodextrin-based formulations approved for clinical use.

Mechanistic Insights: Improved Bioavailability and Targeted Delivery

The dramatic improvements in bioavailability achieved through nanocarrier-based delivery of phytopharmaceuticals arise from multiple synergistic mechanisms operating at different levels of biological organization. At the formulation level, encapsulation within nanocarriers fundamentally alters the physicochemical presentation of hydrophobic phytochemicals to biological systems, converting crystalline or amorphous solids with minimal aqueous solubility into nanoscale dispersions with vastly increased effective surface area and dissolution rates. According to the Noyes-Whitney equation, dissolution rate is directly proportional to surface area, and the nanoscale dimensions of carriers provide surface area to volume ratios orders of magnitude greater than bulk materials. Furthermore, the molecular or amorphous state of drugs within many nanocarrier systems eliminates the energy barrier associated with crystal lattice disruption, enabling more rapid dissolution and supersaturation phenomena that transiently maintain elevated concentrations driving absorption.

Stabilization against chemical and enzymatic degradation represents a critical mechanism by which nanoencapsulation preserves the structural integrity and biological activity of labile phytochemicals. Physical encapsulation within lipid cores, polymer matrices, or liposomal membranes creates a protective microenvironment that shields reactive functional groups from oxidative species, hydrolytic enzymes, and extremes of pH encountered during gastrointestinal transit. For instance, curcumin encapsulated in lipid nanoparticles demonstrates stability at pH 7.4 for extended periods, whereas free curcumin degrades within minutes under identical conditions. The carrier matrix can be further engineered with antioxidants or pH-buffering agents to enhance stability, while surface coatings can provide additional barriers against enzymatic attack. This stabilization extends the temporal window during which intact drug molecules are available for absorption, fundamentally altering the kinetics of drug input into systemic circulation.

Enhanced cellular uptake through endocytic pathways constitutes another crucial mechanism underlying the bioavailability improvements observed with nanoformulated phytochemicals. While passive diffusion across lipid membranes dominates uptake of small lipophilic drugs, nanoparticles are internalized through active, energy-dependent endocytic processes including clathrin-mediated endocytosis, caveolae-mediated uptake, macropinocytosis, and phagocytosis. The specific endocytic pathway engaged depends on nanoparticle size, shape, surface charge, and surface chemistry, with particles between 50 and 200 nanometers preferentially utilizing clathrin-coated pits while larger particles engage macropinocytosis or phagocytosis. Cationic nanoparticles demonstrate enhanced cellular association through electrostatic interactions with negatively charged cell membranes, while surface modification with cell-penetrating peptides or targeting ligands further promotes cellular internalization through receptor-mediated mechanisms. Following endocytic uptake, nanocarriers accumulate in endosomal compartments where acidification

and enzymatic activity can trigger drug release, providing intracellular delivery that bypasses apical efflux transporters responsible for limiting absorption of many phytochemicals.

Lymphatic uptake following oral administration represents an alternative absorption pathway that has emerged as particularly important for nanocarrier-based delivery systems. Lipid-based nanocarriers including lipid nanoparticles and nanoemulsions can be incorporated into chylomicrons formed during lipid digestion and secreted into intestinal lymphatics, bypassing first-pass hepatic metabolism and directly entering systemic circulation via the thoracic duct. This lymphatic transport route is especially relevant for highly lipophilic drugs with log P values exceeding 5, which partition preferentially into the lipid core of chylomicrons. Studies using mesenteric lymph duct cannulation in rodent models have demonstrated that lipid nanocarrier formulations can increase lymphatic transport of phytochemicals by factors of 10 to 100-fold compared to simple solutions, dramatically reducing hepatic extraction and improving systemic bioavailability. Furthermore, lymphatic uptake may provide therapeutic advantages for diseases involving the lymphatic system including certain cancers and infectious diseases.

Modulation of efflux transporter activity represents yet another mechanism contributing to enhanced bioavailability of nanoformulated phytochemicals. P-glycoprotein and other ATP-binding cassette efflux pumps expressed at high levels in intestinal epithelium, blood-brain barrier, and tumor cells actively extrude numerous phytochemicals, substantially limiting their intracellular accumulation and systemic absorption. Nanocarrier-mediated delivery can circumvent efflux through several mechanisms including direct delivery to cytoplasm via endosomal escape, saturating transporter capacity through localized high concentrations following endocytic release, and incorporating efflux pump inhibitors within the formulation. Certain excipients commonly employed in nanoformulations including polysorbates, Cremophor, and polyethylene glycol exhibit P-glycoprotein inhibitory activity, contributing to the overall bioavailability enhancement observed with these systems. Additionally, rapid membrane fusion of some liposomal formulations can deliver drug molecules directly into the cytoplasm without trafficking through endosomal compartments, completely bypassing efflux pump recognition.

Targeted delivery to specific tissues, cells, or subcellular compartments represents a transformative capability of nanotechnology-based systems that fundamentally distinguishes them from conventional formulations. Passive targeting through the enhanced permeability and retention effect exploits the pathophysiological characteristics of tumor tissue and inflamed sites, where abnormal angiogenesis produces fenestrated vasculature with pore sizes ranging from 100 to 780 nanometers, combined with impaired lymphatic drainage that promotes nanoparticle accumulation. Long-circulating nanocarriers with diameters between 10 and 200 nanometers exhibit preferential extravasation through these vascular defects while remaining confined within normal vasculature characterized by tight endothelial junctions, achieving 10 to 50-fold higher tumor accumulation compared to free drugs. However, the enhanced permeability and retention effect shows considerable heterogeneity across tumor types and even within individual tumors, with recent evidence suggesting its contribution may be more limited in human cancers compared to experimental animal models.

Active targeting strategies employ surface-conjugated ligands that recognize and bind specific molecular markers overexpressed on target cells, promoting receptor-mediated endocytosis and enhancing cellular uptake selectivity. Folate-conjugated nanocarriers target the folate receptor frequently overexpressed in epithelial cancers, antibody-conjugated systems recognize tumor-associated antigens such as HER2 or EGFR, and peptide-decorated nanoparticles bind integrins upregulated in tumor vasculature. Aptamers and small molecule ligands including transferrin, lactoferrin, and hyaluronic acid provide additional targeting options with distinct specificity profiles. The surface density of targeting ligands must be carefully optimized, as excessive ligand densities can impair circulation time through enhanced clearance while insufficient densities provide minimal targeting benefit. Dual-targeting strategies combining passive enhanced permeability and retention effect accumulation with active ligand-mediated uptake demonstrate superior tumor localization compared to either mechanism alone.

Stimuli-responsive nanocarriers represent an advanced targeting strategy that maintains drug sequestration during circulation but triggers release in response to specific physiological or pathological cues characteristic of disease sites. pH-responsive systems exploit the acidic microenvironment of tumors, inflamed tissues, and endosomal compartments, incorporating acid-labile linkages or pH-sensitive polymers that undergo protonation-induced conformational changes or degradation at reduced pH. Temperature-sensitive liposomes composed of thermotropic lipids undergo phase transitions at specified temperatures, dramatically increasing membrane permeability and releasing encapsulated contents when local hyperthermia is applied to tumor regions. Redox-responsive nanocarriers utilize disulfide bonds that remain stable in oxidizing extracellular environments but are rapidly cleaved by glutathione present at millimolar concentrations within cells, enabling intracellular drug release following endocytic uptake. Enzyme-responsive systems incorporate substrates for proteases or phospholipases overexpressed in disease sites, triggering carrier degradation and drug release upon enzymatic cleavage.

Table 3: Preclinical studies showing improved pharmacokinetics, efficacy, and targeted delivery using nanocarriers

Phytochemical	Nanocarrier Type	Animal Model	Pharmacokinetic Improvement	Efficacy Outcome	Targeting Strategy
Curcumin	PLGA nanoparticles	Mice with breast cancer xenografts	9-fold increase in AUC, 5-fold increase in half-life	62% tumor volume reduction vs. 23% with free drug	Passive EPR effect
Resveratrol	Solid lipid nanoparticles	Rat oral bioavailability study	8.7-fold increase in bioavailability, prolonged Tmax	Enhanced antioxidant activity in plasma	N/A
Quercetin	PEGylated liposomes	Mice with lung inflammation	11-fold increase in lung accumulation	78% reduction in inflammatory markers	Passive accumulation at inflammation site
EGCG	Chitosan nanoparticles	Rats with liver fibrosis	6.2-fold increase in liver targeting	54% reduction in fibrosis score	Hepatocyte targeting
Silymarin	Nanoemulsion	Mice with acetaminophen hepatotoxicity	4.8-fold increase in bioavailability	Complete prevention of liver damage	Enhanced dissolution and absorption
Berberine	Transferrin-conjugated liposomes	Mice with glioma	7.3-fold increase in brain delivery	3.5-fold increase in survival time	Transferrin receptor-mediated BBB crossing
Paclitaxel	Albumin nanoparticles	Mice with ovarian cancer	33% increase in tumor accumulation	86% tumor growth inhibition vs. 47% with Taxol	gp60 receptor-mediated transcytosis
Artemisinin	Folate-decorated PLGA-PEG	Mice with colorectal cancer	5.4-fold increase in tumor targeting	Complete tumor regression in 40% of animals	Folate receptor targeting

Preclinical Studies and *In vivo* Evidence

Extensive preclinical investigations across diverse disease models have generated compelling evidence supporting the therapeutic advantages of nanoformulated phytopharmaceuticals relative to conventional delivery approaches. Curcumin nanoformulations exemplify the transformative potential of nanotechnology-based delivery, with numerous studies demonstrating dramatic improvements in bioavailability, tissue distribution, and therapeutic efficacy across cancer, inflammatory, and neurodegenerative disease models. Polymeric nanoparticles fabricated from poly lactic-co-glycolic acid and loaded with curcumin have shown up to nine-fold increases in area under the curve and elimination half-life extending from 30 minutes to over four hours in rodent pharmacokinetic studies. These pharmacokinetic enhancements translated to superior anticancer efficacy in xenograft models of breast, prostate, and lung cancer, with nanoformulated curcumin achieving tumor growth inhibition of 60 to 80 percent compared to 20 to 30 percent with equivalent doses of free curcumin.

Resveratrol nanoformulations have similarly demonstrated marked improvements in oral bioavailability and therapeutic outcomes in preclinical models of cardiovascular disease, metabolic syndrome, and cancer. Solid lipid nanoparticle formulations of resveratrol exhibited absolute bioavailability of approximately 42 percent in rats compared to less than 5 percent for free resveratrol administered in aqueous suspension, representing nearly a 10-fold improvement. This enhanced systemic exposure correlated with superior cardioprotective effects in myocardial ischemia-reperfusion injury models, where nanoformulated resveratrol reduced infarct size by 65 percent compared to 28 percent reduction with free drug at equivalent doses. Mechanistic studies revealed that nanoformulation not only increased plasma concentrations but also enhanced tissue penetration, with 3.5-fold higher myocardial resveratrol levels observed following administration of lipid nanoparticles.

Quercetin encapsulated in PEGylated liposomes has shown remarkable efficacy in preclinical models of acute and chronic inflammation, achieving targeted accumulation in inflamed tissues through both enhanced vascular permeability and active recruitment mechanisms. In lipopolysaccharide-induced acute lung injury models, liposomal quercetin demonstrated 11-fold greater lung accumulation compared to free quercetin, resulting in dramatic reductions in neutrophil infiltration, cytokine production, and histopathological damage scores. The nanoformulation reduced pulmonary edema by 72 percent and improved survival from 40 percent to 85 percent in this otherwise lethal inflammatory challenge. Similar benefits were observed in chronic inflammatory conditions including arthritis and inflammatory bowel disease, where sustained release from long-circulating liposomes provided prolonged anti-inflammatory effects with reduced dosing frequency.

Green tea polyphenol epigallocatechin gallate represents another phytochemical where nanoformulation has overcome severe stability and bioavailability limitations to unlock therapeutic potential. Chitosan nanoparticles protecting epigallocatechin gallate from degradation and promoting intestinal absorption achieved 6.2-fold increases in oral bioavailability compared to free compound administered as aqueous solution. In experimental models of non-alcoholic fatty liver disease, nanoformulated epigallocatechin gallate reduced hepatic steatosis by 68 percent, decreased inflammatory infiltration by 71 percent, and lowered fibrosis scores by 54 percent, substantially outperforming free compound which showed minimal efficacy. Biodistribution studies revealed preferential hepatic accumulation of chitosan nanoparticles following oral administration, potentially attributable to hepatocyte-specific uptake mechanisms and the positive charge-mediated interactions with liver sinusoidal endothelium.

Silymarin nanoformulations have demonstrated exceptional promise in preclinical models of liver disease, addressing the primary therapeutic target of this hepatoprotective flavonolignan while overcoming its extremely poor aqueous solubility and erratic absorption. Nanoemulsion formulations achieved 4.8-fold increases in oral bioavailability through

enhanced solubilization and lymphatic absorption, translating to complete protection against acetaminophen-induced hepatotoxicity in mouse models at doses where free silymarin provided minimal benefit. Biochemical markers including alanine aminotransferase, aspartate aminotransferase, and bilirubin remained at normal levels following acetaminophen challenge in animals receiving nanoformulated silymarin, while dramatic elevations occurred in controls receiving free drug or vehicle. Histopathological examination confirmed complete preservation of normal hepatic architecture without necrosis, inflammation, or fibrosis in nanoformulation-treated groups.

Berberine-loaded nanocarriers have shown remarkable success in delivering this antimicrobial and metabolic regulatory alkaloid across biological barriers including the blood-brain barrier, enabling applications in neurodegenerative diseases previously inaccessible due to poor brain penetration. Transferrin-conjugated liposomes exploiting transferrin receptor-mediated transcytosis achieved 7.3-fold increases in brain delivery of berberine compared to free drug, with particular accumulation in tumor tissue in glioma models. This enhanced brain delivery translated to 3.5-fold prolongation of median survival time in orthotopic glioma-bearing mice, with tumor volumes reduced by 76 percent relative to controls. Mechanistic studies demonstrated that the nanoformulation not only enhanced blood-brain barrier penetration but also promoted tumor cell uptake through transferrin receptor-mediated endocytosis, as glioma cells overexpress transferrin receptors to support their high metabolic demands.

Paclitaxel, although now synthetically produced, was originally isolated from yew trees and remains a clinically important phytopharmaceutical whose delivery has been revolutionized by nanotechnology. The albumin-bound paclitaxel nanoparticle formulation approved for clinical use demonstrated superior efficacy compared to conventional Cremophor-based formulation in preclinical xenograft models across multiple cancer types. Mechanistic studies revealed that albumin nanoparticles achieve 33 percent higher intratumoral paclitaxel concentrations through gp60-mediated transcytosis across tumor endothelium and SPARC-mediated retention in tumor stroma. These pharmacokinetic advantages translated to 86 percent tumor growth inhibition with nanoparticle formulation compared to 47 percent with conventional formulation at equivalent paclitaxel doses.

Artemisinin and its derivatives, despite being first-line antimalarials with established efficacy, have benefited from nanoformulation approaches aimed at improving pharmacokinetics, reducing dosing frequency, and targeting parasitized erythrocytes. Folate-decorated poly lactic-co-glycolic acid-polyethylene glycol nanoparticles demonstrated 5.4-fold higher accumulation in tumor tissue in colorectal cancer xenograft models, exploiting folate receptor overexpression characteristic of many cancers. The targeted nanoformulation achieved complete tumor regression in 40 percent of treated animals, while free artemisinin showed only modest tumor growth delay without any complete responses. These findings have spurred interest in repurposing artemisinin derivatives as anticancer agents when delivered via targeted nanocarriers.

Comparative studies directly evaluating multiple nanocarrier platforms for the same phytochemical have provided valuable insights into optimal formulation selection based on disease type and administration route. For curcumin, liposomal formulations generally demonstrated superior bioavailability enhancement following intravenous administration, while lipid nanoparticles and nanoemulsions showed advantages for oral delivery due to enhanced intestinal absorption and lymphatic uptake. Polymer-drug conjugates provided the most sustained release and prolonged circulation but required chemical modification of curcumin that might alter biological activity. These comparative evaluations underscore the importance of matching carrier properties to specific therapeutic objectives and delivery requirements.

Clinical Translation and Human Studies

The translation of nanotechnology-based phytopharmaceutical delivery systems from preclinical models to clinical application in humans represents a critical juncture where promising experimental findings must demonstrate safety, feasibility, and therapeutic benefit in heterogeneous patient populations. Several nanoformulated plant-derived compounds have progressed through clinical evaluation, providing proof-of-concept evidence for the translational potential of these technologies while revealing important challenges specific to human application. The albumin-bound paclitaxel nanoparticle formulation stands as the most successful example of clinically approved phytopharmaceutical nanotechnology, having demonstrated superior efficacy and reduced toxicity compared to conventional Cremophor-based formulation across multiple Phase III trials in metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer.

The pivotal Phase III trial in metastatic breast cancer enrolled 454 patients randomized to receive either albumin-bound paclitaxel nanoparticles at 260 milligrams per square meter or conventional paclitaxel at 175 milligrams per square meter, both administered every three weeks. The nanoparticle formulation demonstrated statistically significant improvements in objective response rate reaching 33 percent compared to 19 percent with conventional formulation, and progression-free survival extending to 23 weeks versus 17 weeks. Notably, these efficacy advantages were achieved despite the nanoparticle formulation being administered without premedication for hypersensitivity reactions, which are required for Cremophor-based paclitaxel and contribute to patient burden. The incidence of severe hypersensitivity reactions was reduced from 2 percent to less than 1 percent with the nanoparticle formulation, attributed to elimination of Cremophor vehicle. These clinical results validated the mechanistic hypothesis that albumin-mediated transcytosis enhances tumor delivery of paclitaxel while improving tolerability through elimination of toxic solubilizing agents.

Curcumin nanoformulations have advanced into early-phase clinical trials evaluating pharmacokinetics, safety, and preliminary efficacy signals in various malignant and inflammatory conditions. A Phase I dose-escalation study of polymeric nanoparticle curcumin in patients with advanced solid tumors demonstrated excellent tolerability at doses up to 300 milligrams daily administered orally for 21-day cycles. Pharmacokinetic analysis revealed dose-proportional increases in plasma curcumin concentrations, with maximum concentrations and area under the curve values approximately 22-fold and 16-fold higher respectively compared to historical data from equivalent doses of non-formulated curcumin. Notably, peak plasma concentrations approached one micromolar, a threshold generally considered necessary

for biological activity based on *in vitro* studies, whereas free curcumin rarely achieves nanomolar concentrations even at gram-level doses. Disease stabilization was observed in several patients with refractory cancers, providing preliminary evidence of potential therapeutic benefit warranting further investigation.

A randomized controlled trial evaluated nano-curcumin supplementation in patients with non-alcoholic fatty liver disease, enrolling 84 subjects randomized to receive either 80 milligrams nano-curcumin daily or placebo for 12 weeks. The nano-curcumin group demonstrated statistically significant reductions in hepatic steatosis assessed by ultrasound, with mean improvement scores of 38 percent compared to 11 percent in the placebo group. Serum biomarkers of liver function including alanine aminotransferase and aspartate aminotransferase decreased by 28 percent and 24 percent respectively in the nano-curcumin group while remaining stable in controls. Inflammatory markers including C-reactive protein and tumor necrosis factor alpha showed 41 percent and 36 percent reductions with active treatment. These findings suggest that enhanced bioavailability achieved through nanoformulation enables curcumin to reach concentrations sufficient for clinically meaningful effects on liver inflammation and steatosis.

Quercetin-loaded nanoparticles have been evaluated in Phase II trials for chronic obstructive pulmonary disease, building on preclinical evidence of anti-inflammatory and antioxidant effects in lung tissue. A multicenter trial randomized 156 patients with moderate to severe chronic obstructive pulmonary disease to receive either quercetin phytosome nanoparticles at 200 milligrams twice daily or placebo for 24 weeks as adjunct to standard bronchodilator therapy. The primary endpoint of change in forced expiratory volume in one second from baseline showed statistically significant improvement of 127 milliliters in the nanoparticle group compared to 43 milliliters in placebo group. Secondary endpoints including six-minute walk distance, dyspnea scores, and exacerbation rates also favored the nanoparticle treatment. Biomarker analyses revealed reductions in systemic inflammatory markers and oxidative stress indicators, consistent with the proposed anti-inflammatory mechanism of action. However, the modest magnitude of functional improvements and unclear long-term benefits necessitate larger confirmatory trials before definitive conclusions regarding clinical utility.

Silymarin phosphatidylcholine complex, which can be considered an early form of lipid-based nanoformulation, has undergone extensive clinical evaluation in various liver diseases with generally favorable though sometimes inconsistent results. A meta-analysis of 13 randomized controlled trials including over 900 patients with alcoholic liver disease and viral hepatitis concluded that silymarin supplementation significantly improved liver function tests and histological features of liver damage. However, substantial heterogeneity in study designs, doses, formulations, and patient populations limited the strength of conclusions. More recent trials specifically utilizing advanced nanoformulations with enhanced bioavailability have shown more consistent benefits, suggesting that previous inconsistent results may have reflected inadequate systemic exposure due to poor absorption of conventional formulations.

Green tea polyphenol formulations have been evaluated in numerous clinical trials for cancer prevention, metabolic syndrome, and neurodegenerative diseases, though few studies have specifically utilized well-characterized nanoformulations. A Phase II chemoprevention trial in patients with oral premalignant lesions evaluated a liposomal green tea extract formulation delivering 400 milligrams epigallocatechin gallate daily for 12 weeks. The nanoformulated treatment demonstrated significantly higher plasma concentrations of epigallocatechin gallate compared to historical controls receiving non-formulated extracts at equivalent doses. Clinical response defined as complete or partial resolution of lesions occurred in 58 percent of patients, substantially higher than the 20 to 30 percent response rates typically observed with conventional formulations. Molecular analyses of biopsy specimens revealed reduced proliferation indices and increased apoptosis in responders, supporting engagement of relevant biological targets.

Despite these encouraging preliminary results, several challenges have emerged regarding clinical translation of phytopharmaceutical nanoformulations. Optimal dosing remains uncertain for many formulations, as improved bioavailability may necessitate dose reductions to avoid toxicity while the exact dose-response relationships are poorly defined. The lack of validated biomarkers to confirm target engagement and predict response hinders rational dose optimization and patient selection. Manufacturing challenges including batch-to-batch consistency, scalability, and stability during storage have complicated development of some promising formulations. Regulatory pathways for nanoformulated botanical products remain incompletely defined, with uncertainty regarding requirements for chemistry, manufacturing, and controls characterization of complex plant extracts combined with nanoscale carriers. The higher costs associated with nanoformulation manufacturing and quality control may limit accessibility and reimbursement unless clear clinical advantages justify premium pricing.



Fig 3: Translational pathway from preclinical nanopharmaceutical evaluation to clinical application in humans

Safety, Toxicity, and Regulatory Considerations

The safety profile of nanoformulated phytopharmaceuticals represents a critical determinant of their translational potential and clinical acceptance, requiring comprehensive evaluation of both the bioactive phytochemical and the nanocarrier system itself. While phytochemicals are often perceived as inherently safe due to their natural origin, this assumption is not uniformly valid, as many plant-derived compounds exhibit dose-dependent toxicity, and the dramatically enhanced bioavailability achieved through nanoformulation can unmask adverse effects not observed with poorly absorbed conventional preparations. Conversely, nanocarrier materials themselves may introduce novel toxicity concerns related to their nanoscale dimensions, large surface areas, unique physicochemical properties, and potential for biological persistence and accumulation. Concerns regarding nanoparticle toxicity have focused primarily on particle size-dependent cellular uptake and intracellular trafficking patterns that differ fundamentally from bulk materials. Nanoparticles below 100 nanometers can penetrate cellular membranes more readily, access intracellular organelles including mitochondria and nuclei, and potentially interfere with normal cellular processes. Metal and metal oxide nanoparticles including silver, gold, and titanium dioxide have shown size-dependent cytotoxicity in various cell lines, with smaller particles generally exhibiting greater toxicity attributable to enhanced cellular uptake, increased surface reactivity, and oxidative stress generation. However, the biodegradable polymers and lipids commonly employed in pharmaceutical nanoformulations generally demonstrate excellent biocompatibility when properly characterized and controlled.

Poly lactic-co-glycolic acid and polylactic acid have been extensively evaluated in preclinical and clinical studies, with decades of safe use in FDA-approved products including surgical sutures and parenteral drug formulations. These polymers degrade hydrolytically to lactic acid and glycolic acid, normal metabolites that are readily cleared through the tricarboxylic acid cycle without accumulation. *In vitro* and *in vivo* toxicity studies have consistently demonstrated minimal cytotoxicity, genotoxicity, or immunotoxicity at relevant concentrations. However, localized acidification resulting from polymer degradation can cause tissue irritation at injection sites, and certain formulations have shown mild inflammatory responses attributed to particulate matter recognition by macrophages. These effects are generally transient and resolve following complete polymer degradation and clearance.

Lipid-based nanocarriers including liposomes, solid lipid nanoparticles, and nanoemulsions benefit from composition based on physiological lipids and generally recognized as safe excipients, providing inherent biocompatibility advantages. Phosphatidylcholine, the primary component of many liposomal formulations, is a major constituent of cell membranes and demonstrates excellent safety in parenteral administration. However, the inclusion of synthetic lipids, cholesterol derivatives, or PEGylated lipids introduces components not normally present at high concentrations *in vivo*, necessitating careful toxicological evaluation. Repeated administration of PEGylated nanocarriers has been associated with accelerated blood clearance phenomenon in some studies, attributed to anti-polyethylene glycol antibody production that enhances clearance of subsequent doses. This immunological response can diminish the pharmacokinetic advantages of PEGylation and potentially cause hypersensitivity reactions, though clinical significance remains debated.

Chitosan nanoparticles, despite being derived from natural sources, have shown dose-dependent toxicity related to the positive surface charge that can disrupt cellular membranes and cause hemolysis at high concentrations. Modification of surface charge through PEGylation or other chemical modifications can substantially reduce these toxic effects while maintaining beneficial mucoadhesive properties. Dendrimers, particularly polyamidoamine dendrimers at higher generations, have demonstrated concerning cytotoxicity attributed to cationic surface groups that can disrupt membrane integrity, trigger mitochondrial dysfunction, and induce apoptosis. Surface modification strategies to reduce charge density or shield cationic groups through PEGylation or acetylation can mitigate these effects.

Long-term biodistribution and potential accumulation of non-degradable nanocarrier materials represents an important safety consideration requiring extended observation periods. While biodegradable polymers undergo complete degradation and clearance, metallic nanoparticles may persist in tissues for extended periods, raising concerns about chronic toxicity. Gold nanoparticles, for instance, demonstrate extended tissue retention particularly in liver and spleen, persisting for months after administration. Although gold is generally considered biologically inert, the altered physicochemical properties at the nanoscale and high surface reactivity may produce unanticipated biological effects requiring careful monitoring. Carbon-based nanomaterials including nanotubes and graphene derivatives have shown variable biocompatibility and concerns regarding pulmonary toxicity similar to asbestos when certain structural characteristics are present.

Table 4: Safety, toxicity, and regulatory considerations for phytopharmaceutical nanocarriers

Nanocarrier Type	Primary Safety Concerns	Toxicity Findings	Biodegradation Profile	Regulatory Status	Clinical Approval Examples	Key Regulatory Requirements
PLGA nanoparticles	Local inflammation, acidification	Minimal systemic toxicity, transient inflammation	Complete degradation in weeks to months	Generally regarded as safe	Multiple approved products	CMC characterization, stability data
Liposomes	Hypersensitivity, complement activation	Generally safe, dose-dependent tolerability	Rapid clearance via RES	Established precedent	Doxil, Ambisome, Onpattro	Lipid characterization, stability, sterility
Lipid nanoparticles	Lipid accumulation, hepatotoxicity	Generally safe at therapeutic doses	Enzymatic degradation	Emerging pathway	COVID-19 vaccines	Lipid quality, particle size, stability
PEGylated systems	Accelerated blood clearance, anti-PEG antibodies	Variable immunogenicity	Depends on core material	Established for some products	Pegasys, Neulasta	PEG characterization, immunogenicity assessment
Chitosan nanoparticles	Hemolysis, charge-mediated toxicity	Dose-dependent cytotoxicity	Enzymatic degradation	Limited regulatory precedent	None approved	Source characterization, molecular weight, deacetylation degree
Gold nanoparticles	Tissue accumulation, long-term persistence	Size-dependent toxicity, generally well-tolerated	Minimal degradation	Investigational	None approved for systemic use	Comprehensive toxicology, biodistribution
Dendrimers	Membrane disruption, hemolysis	Generation-dependent cytotoxicity	Limited degradation	Investigational	None approved	Surface modification, toxicology studies
Albumin nanoparticles	Generally minimal	Excellent safety profile	Proteolytic degradation	Approved pathway	Abraxane	Protein characterization, aggregation assessment

Genotoxicity represents a critical safety endpoint requiring thorough evaluation for any pharmaceutical product, with particular attention for nanoformulations due to potential nuclear penetration of ultrasmall particles. Bacterial reverse mutation assays, chromosomal aberration tests, and *in vivo* micronucleus assays constitute standard batteries for genotoxicity assessment. Most lipid and polymer-based pharmaceutical nanocarriers have demonstrated negative results across these assays when properly formulated, though some metallic nanoparticles have shown positive results in certain test systems. The relevance of positive *in vitro* genotoxicity findings at high concentrations far exceeding therapeutic exposures remains debated, emphasizing the importance of appropriate dose selection and integration of *in vivo* confirmation studies.

Immunotoxicity assessment has gained prominence given the recognition that nanoparticle size, shape, and surface properties can influence immune system recognition and response. Complement activation represents a particular concern for intravenously administered nanocarriers, as certain formulations can trigger complement cascade activation leading to production of anaphylatoxins and potentially severe hypersensitivity reactions. Liposomal formulations and lipid nanoparticles have shown variable propensity for complement activation depending on lipid composition and surface characteristics. PEGylation generally reduces complement activation, though paradoxically may promote production of anti-polyethylene glycol antibodies upon repeated dosing. Comprehensive immunotoxicity evaluation should include assessment of complement activation, antibody production, cytokine release, and impacts on immune cell populations and functions.

Regulatory frameworks for nanomedicine products remain in evolution, with regulatory agencies worldwide working to establish appropriate guidance documents addressing unique characteristics of these products. The FDA has released several guidance documents relevant to nanotechnology including considerations for chemistry, manufacturing, and controls, quality considerations, and safety assessments. However, no unified regulatory definition of nanomedicine exists, and review approaches vary depending on product classification as drug, biological product, combination product, or medical device. For phytopharmaceutical nanoformulations classified as botanical drug products, additional complexity arises from requirements to characterize the botanical source material, extraction and purification methods, and consistency of phytochemical composition.

Chemistry, manufacturing, and controls documentation for nanoformulations must demonstrate reproducible anufacturing processes capable of consistent production of particles with specified critical quality attributes including size distribution, surface charge, morphology, drug loading, and release characteristics. Analytical methods with appropriate validation must be established for all quality attributes, presenting challenges given the complex nature of nanoparticulate systems. Stability studies must evaluate both physical stability of the nanocarrier structure and chemical stability of the encapsulated phytochemical under stressed and accelerated conditions. Aggregation, drug leakage, changes in particle size, and chemical degradation represent common stability failure modes requiring monitoring. Scaling up manufacturing from laboratory to commercial scale represents a substantial challenge for many nanoformulation technologies, as processes involving high-energy emulsification, precise temperature control, or complex multi-step procedures can be difficult to reproduce at large scale while maintaining quality attributes. Process analytical technologies including in-line particle size monitoring, real-time drug content analysis, and statistical process control become essential for ensuring batch-to-batch consistency. The relatively high costs associated with specialized equipment, quality control testing, and complex manufacturing processes can substantially increase production expenses compared to conventional formulations, necessitating clear evidence of clinical advantages to justify premium pricing.

Future Perspectives: Personalized Phytopharmaceutical Nanotherapy

The future of phytopharmaceutical delivery increasingly lies in integration with precision medicine paradigms that recognize individual variability in disease pathophysiology, genetic polymorphisms affecting drug metabolism, and heterogeneity in treatment response. Personalized nanomedicine approaches could enable optimization of nanocarrier properties, drug selection, and dosing regimens based on individual patient characteristics, biomarker profiles, and real-time therapeutic monitoring. Genetic polymorphisms in drug-metabolizing enzymes including cytochrome P450 isoforms and conjugating enzymes substantially influence phytochemical metabolism and systemic exposure. Individuals with rapid metabolizer phenotypes may benefit from controlled-release nanoformulations that maintain therapeutic concentrations despite accelerated clearance, while poor metabolizers might require dose reductions even with nanoformulated products to avoid toxicity.

Tumor heterogeneity represents a major challenge in oncology that could be addressed through combinatorial nanocarrier strategies delivering multiple phytochemicals targeting distinct pathways or cellular populations. Single nanocarriers co-loaded with synergistic phytochemicals, or combinations of different nanocarrier types each loaded with complementary agents, could provide more comprehensive anticancer effects than monotherapy approaches. Sequential targeting strategies employing initial administration of priming nanocarriers that modulate tumor microenvironment followed by therapeutic nanocarriers may enhance treatment efficacy. For instance, nanocarriers delivering antiangiogenic phytochemicals could normalize tumor vasculature, improving perfusion and enhancing subsequent delivery of cytotoxic agents.

Theranostic nanoplatforms integrating therapeutic and diagnostic capabilities within single nanocarrier systems represent an emerging paradigm with particular promise for phytopharmaceuticals. Incorporation of imaging agents including fluorescent dyes, radionuclides, or magnetic resonance contrast agents enables real-time visualization of nanocarrier biodistribution, tumor accumulation, and drug release. This imaging capability facilitates assessment of whether individual patients exhibit favorable nanocarrier pharmacokinetics and tumor targeting that predict treatment response, enabling patient selection and early identification of non-responders who might benefit from alternative approaches. Stimuli-responsive theranostic systems could enable externally triggered drug release at sites of nanocarrier accumulation, maximizing local drug concentrations while minimizing systemic exposure.

Artificial intelligence and machine learning approaches are increasingly being applied to nanoformulation design and optimization, potentially accelerating development timelines and reducing empirical trial-and-error approaches. Quantitative structure-activity relationship models can predict optimal nanocarrier characteristics for specific phytochemicals based on molecular properties including log P, molecular weight, hydrogen bonding capacity, and chemical structure. Machine learning algorithms trained on existing nanoformulation databases can identify patterns linking formulation parameters to performance outcomes including encapsulation efficiency, stability, and *in vivo* pharmacokinetics. These predictive models could guide rational formulation design, reducing the number of experimental iterations required to achieve target product profiles.

Biomimetic nanocarriers exploiting natural biological structures and transport mechanisms represent a frontier area with potential to enhance targeting specificity and reduce immunogenicity. Cell membrane-coated nanoparticles prepared by fusing cell membranes from red blood cells, platelets, cancer cells, or immune cells onto synthetic nanoparticle cores inherit surface proteins and biological recognition properties from the source cells. Red blood cell membrane coating confers prolonged circulation through CD47-mediated self-recognition signals that inhibit phagocytosis, while cancer cell membrane coating enables homotypic targeting to matching cancer types through adhesion molecule interactions. Exosome-based delivery systems leverage naturally occurring extracellular vesicles for intercellular communication, offering inherent biocompatibility and cell-specific targeting capabilities.

Oral delivery of macromolecular phytochemicals and plant-derived biologics represents an area where advanced nanoformulation strategies could enable new therapeutic applications. Plant-produced recombinant proteins, therapeutic peptides from plant sources, and complex phytochemical mixtures with synergistic effects could benefit from nanocarrier-mediated protection against gastrointestinal degradation and enhanced intestinal absorption. Mucoadhesive and mucus-penetrating nanocarriers designed to navigate the complex intestinal mucus barrier could substantially improve bioavailability of these challenging compounds. Targeted delivery to gut-associated lymphoid tissue might enable oral vaccination or modulation of intestinal immunity using plant-derived immunomodulatory compounds.

Combination products integrating nanoformulated phytochemicals with conventional pharmaceuticals could provide synergistic therapeutic effects while potentially reducing doses and toxicity of synthetic drugs. For instance, nanocarriers co-delivering curcumin with chemotherapy agents have shown synergistic anticancer effects in preclinical models, with the phytochemical enhancing chemosensitivity through multiple mechanisms including inhibition of drug resistance pathways. Careful pharmacokinetic optimization is required to ensure both components reach target sites simultaneously at appropriate concentration ratios for optimal synergy. Regulatory pathways for these combination products remain complex, requiring demonstration that each component contributes meaningfully to therapeutic effect.

Three-dimensional bioprinting technologies combined with nanoformulated phytochemicals could enable creation of personalized tissue scaffolds for regenerative medicine applications. Bioinks containing nanoencapsulated growth factors, anti-inflammatory phytochemicals, and antimicrobial plant compounds could be spatially patterned to guide tissue regeneration, control inflammation, and prevent infection in wound healing or tissue engineering applications. The controlled release characteristics of nanocarriers would enable sustained delivery of bioactive factors throughout the tissue maturation process. This convergence of nanotechnology, phytotherapy, and bioprinting represents a highly innovative direction for future investigation.

Point-of-care manufacturing of personalized nanoformulations using microfluidic or 3D printing

technologies could enable on-demand production tailored to individual patient needs. Microfluidic mixing devices can produce nanocarriers with highly controlled size and composition through precise manipulation of flow rates and mixing parameters. Hospital-based manufacturing could allow dose and composition adjustment based on therapeutic drug monitoring or biomarker feedback, moving toward adaptive dosing strategies. However, substantial regulatory and quality assurance challenges would need resolution before such personalized manufacturing approaches could be implemented clinically

Global health applications of phytopharmaceutical nanotechnology represent an important but often overlooked opportunity, particularly for infectious and neglected tropical diseases where plant-derived compounds show promise but conventional formulations demonstrate inadequate efficacy. Artemisinin-based antimalarials, berberine for gastrointestinal infections, and andrographolide for dengue fever exemplify phytochemicals where nanoformulation could enhance therapeutic outcomes in resource-limited settings. However, cost considerations, cold-chain requirements, and manufacturing complexity pose barriers to implementation in low-income regions. Development of thermostable, affordable nanoformulations using locally available materials and simplified manufacturing processes could increase accessibility.

Conclusion

Nanotechnology-based delivery systems have emerged as transformative platforms addressing fundamental limitations in conventional phytopharmaceutical delivery and unlocking the therapeutic potential of plant-derived bioactive compounds. The diverse array of nanocarrier systems including nanoparticles, liposomes, nanoemulsions, polymeric carriers, and dendrimers each offer distinct advantages in terms of loading capacity, stability, release kinetics, and targeting capabilities that can be matched to specific phytochemical properties and therapeutic requirements. Multiple synergistic mechanisms including enhanced solubilization, protection from degradation, facilitated cellular uptake, evasion of efflux transporters, lymphatic absorption, and targeted delivery collectively contribute to the dramatic pharmacokinetic improvements consistently observed with nanoformulated phytochemicals across preclinical models.

Extensive preclinical evidence across animal models of cancer, inflammation, metabolic disease, and neurodegeneration has demonstrated superior efficacy of nanoformulated phytochemicals compared to conventional formulations, with improvements in tissue distribution, therapeutic index, and duration of action. Early clinical studies have begun validating these preclinical findings in human populations, with several nanoformulations demonstrating enhanced bioavailability, favorable safety profiles, and encouraging preliminary efficacy signals. The clinical success of albumin-bound paclitaxel nanoparticles across multiple cancer types provides definitive proof-of-concept that nanotechnology can translate into improved patient outcomes for phytopharmaceuticals.

However, substantial challenges remain before nanoformulated phytochemicals achieve widespread clinical adoption. Manufacturing complexity, scalability limitations, stability concerns, and high production costs pose practical barriers to commercial development. Incomplete understanding of long-term safety profiles for novel nanocarrier materials necessitates comprehensive toxicological evaluation. Regulatory pathways for botanical nanomedicines remain in evolution, with uncertainty regarding approval requirements. The need for specialized analytical techniques to characterize nanoformulations and the challenges of maintaining batch-to-batch consistency complicate quality control. Additionally, the heterogeneity of patient populations and diseases demands sophisticated approaches to patient selection and treatment optimization.

Future advances will likely focus on personalized nanomedicine approaches integrating genetic, biomarker, and imaging information to optimize nanocarrier design and dosing for individual patients. Theranostic platforms combining therapeutic and diagnostic capabilities will enable real-time monitoring of nanocarrier distribution and treatment response. Biomimetic strategies exploiting natural biological structures may enhance targeting specificity and reduce immunogenicity. Artificial intelligence and machine learning will accelerate formulation optimization and predict clinical outcomes. Combination products integrating nanoformulated phytochemicals with conventional drugs could provide synergistic benefits. The convergence of nanotechnology with precision medicine, bioprinting, and point-of-care manufacturing promises to revolutionize phytopharmaceutical delivery and expand therapeutic applications.

In conclusion, nanotechnology represents a paradigm-shifting approach that addresses long-standing limitations in phytopharmaceutical delivery while preserving and enhancing the inherent biological activities of plant-derived compounds. Continued interdisciplinary collaboration among phytochemists, pharmaceutical scientists, nanotechnologists, clinicians, and regulatory experts will be essential to translate promising experimental findings into clinically viable products that improve patient outcomes. As the field matures and addresses current challenges, nanoformulated phytopharmaceuticals are poised to assume an increasingly important role in modern healthcare, bridging traditional botanical medicine with cutting-edge pharmaceutical sciences to create innovative therapeutic solutions for diverse diseases.

References

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770-803.
2. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, *et al*. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33:1582-1614.
3. Babaei F, Mirzababaei M, Nassiri-Asl M. Quercetin in food: possible mechanisms of its effect on memory. J Food Sci. 2018;83:2280-2287.
4. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. Pharm Res. 1995;12:413-420.
5. Patra JK, Das G, Fraceto LF, *et al*. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71.

6. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807-818.
7. Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of vitamin E TPGS in drug delivery. Eur J Pharm Sci. 2013;49:175-186.
8. Jambhekar SS, Breen P. Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today. 2016;21:356-362.
9. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20-37.
10. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101-124.
11. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941-951.
12. Bonifácio BV, Silva PB, Ramos MA, *et al*. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine. 2014;9:1-15.
13. Aqil F, Munagala R, Jeyabalan J, Vadhanam MV. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013;334:133-141.
14. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47.
15. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
16. Bergstrom CA, Larsson P. Computational prediction of drug solubility in water-based systems: qualitative and quantitative approaches used in the current drug discovery and development setting. Int J Pharm. 2018;540:185-193.
17. Williams HD, Trevaskis NL, Charman SA, *et al*. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315-499.
18. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337-341.
19. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009;11:740-746.
20. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
21. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38:802-832.
22. Wang YJ, Pan MH, Cheng AL, *et al*. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15:1867-1876.
23. Bilia AR, Bergonzi MC, Isacchi B, Antiga E, Caproni M. Flavonoids loaded in nanocarriers: an opportunity to increase oral bioavailability and bioefficacy. Food Nutr Sci. 2014;5:1212-1327.
24. Schneider C, Gordon ON, Edwards RL, Luis PB. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem. 2015;63:7606-7614.
25. Trela BC, Waterhouse AL. Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem. 1996;44:1253-1257.
26. Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol. 2004;44:559-569.
27. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging *in vivo*. Adv Drug Deliv Rev. 2013;65:71-79.
28. Zhang YR, Lin R, Li HJ, He WL, Du JZ, Wang J. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11:e1519.
29. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005;1056:206-217.
30. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58:516-527.
31. Sut S, Faggian M, Baldan V, *et al*. Natural deep eutectic solvents (NADES) to enhance berberine absorption: an *in vivo* pharmacokinetic study. Molecules. 2017;22:1921.
32. Rivera-Burgos D, Regnier FE. Disparities in plant extract composition as a function of botanical source and preparation procedure. Anal Chem. 2014;86:5214-5222.
33. Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. Complement Ther Med. 2012;20:100-106.
34. Calabrese EJ, Baldwin LA. Hormesis: the dose-response revolution. Annu Rev Pharmacol Toxicol. 2003;43:175-197.
35. Kou L, Sun J, Zhai Y, He Z. The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J Pharm Sci. 2013;8:1-10.
36. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
37. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196.
38. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102.
39. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41:2740-2779.
40. Mittal AK, Chisti Y, Banerjee UC. Synthesis of metallic nanoparticles using plant extracts. Biotechnol Adv. 2013;31:346-356.
41. Sperling RA, Rivera Gil P, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev. 2008;37:1896-1908.
42. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
43. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active

targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.
44. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, *et al*. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.
45. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
46. Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased *in vivo* activity. Expert Opin Drug Deliv. 2011;8:565-580.